Health News

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Oncology, Pharmacy, Tumor

Related posts

• Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint (0)
  Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at [...]
  
  
• Regorafenib lengthens lives of patients with metastatic colorectal cancer (0)
  An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal [...]
  
  
• Marshall Edwards Announces Initiation Of Phase I Clinical Trial Of Lead Oncology Drug Candidate ME-143 (0)
  Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors... Read more [tags] Pharmacy News [/tags]
  
  
• Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia (0)
  Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. [...]
  
  
• Genus Oncology, LLC Announces Initiation Of Phase I Trial Of GO-203-2c In Patients With Solid Tumors (0)
  Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has successfully filed an Investigational New Drug (IND) application with the US Food & Drug Administration (FDA) and has dosed the first patient in a Phase I trial to test its lead compound, GO-203-2c, in patients with solid [...]